"GLP-1 drugs work as "moderation molecules," reducing primary desires for things like food or alcohol, giving us quick and easy dopamine. One interesting secondary effect is that this moderation molecule has an alter ego: a "desire dampener" that can "go too far." He notes anecdotal reports of lower sex drives or decreased interest and motivation."
"When we take a medicine in the hope that it will curb a particular desire, we're meddling with a complex system. These drugs may not distinguish between healthy and unhealthy desires—they may just dampen desire altogether, which some may see as a solution."
"Screening tools for depression ask about desire and motivation: Someone with low or absent desire—to get out of bed, meet a partner, pursue a career, or enjoy a meal—may meet criteria for clinical depression. Many clients wish to desire more, not less; some have lost the spark that drives work or relationships, and desiring less could be catastrophic."
GLP-1 medications like Ozempic effectively manage weight and blood sugar but produce an under-discussed side effect: they weaken desire broadly, not just for food. These "moderation molecules" reduce dopamine-seeking behavior but may indiscriminately suppress healthy desires alongside unhealthy ones. Reports indicate decreased sex drive, motivation, and interest in activities. This dampening effect reflects a Victorian moral framework viewing desire as inherently problematic. However, reduced desire mirrors depression symptoms and can harm quality of life. Therapy traditionally helps people reclaim and rebuild desire, recognizing that motivation drives meaningful engagement with work, relationships, and personal fulfillment. The challenge lies in distinguishing between suppressing harmful impulses and eliminating essential human drives.
#glp-1-medications #desire-and-motivation #mental-health-side-effects #depression-symptoms #pharmaceutical-ethics
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]